Morgan Stanley Discount Zert BNTX.../ DE000ME8SUQ8 /
7/25/2024 8:03:39 AM | Chg.+0.01 | Bid8:24:02 AM | Ask8:24:02 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
54.56EUR | +0.02% | 54.60 Bid Size: 300 |
54.97 Ask Size: 300 |
BioNTech SE | - USD | 12/31/2024 | Call |
GlobeNewswire
6/27
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...
GlobeNewswire
6/24
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT...
GlobeNewswire
6/1
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates M...
GlobeNewswire
5/29
BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
GlobeNewswire
5/28
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology ...
GlobeNewswire
5/21
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...
GlobeNewswire
5/21
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announ...
GlobeNewswire
5/17
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
GlobeNewswire
5/17
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
GlobeNewswire
5/9
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
5/2
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
4/22
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire
4/10
Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first...
GlobeNewswire
4/7
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
GlobeNewswire
3/28
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
3/20
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update